Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.85 |
| ▸ | TSHR | P16473 | 1/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26814669 | 0.86 | LMNA (0.79) | HSD17B10LMNAALOX15TSHRSMN1; SMN2 | |
| SCHEMBL3891473 | 0.84 | HSD17B10 (0.75) | HSD17B10LMNAALOX15TSHRSMN1; SMN2 | |
| SCHEMBL12184245 | 0.79 | GAA (0.72) | HSD17B10LMNAALOX15TSHRSMN1; SMN2 | |
| SCHEMBL13753536 | 0.79 | TSHR (0.68) | HSD17B10LMNAALOX15TSHRSMN1; SMN2 | |
| SCHEMBL26828135 | 0.77 | HTT (0.60) | HSD17B10LMNAALOX15TSHRHTT | |
| SCHEMBL26835295 | 0.77 | HTT (0.54) | HSD17B10LMNAALOX15TSHRHTT | |
| SCHEMBL26827255 | 0.76 | HRH4 (0.58) | HSD17B10LMNAALOX15TSHRHTT | |
| SCHEMBL11293119 | 0.74 | GAA (0.85) | HSD17B10LMNAALOX15TSHRSMN1; SMN2 | |
| SCHEMBL26835297 | 0.73 | LMNA (0.47) | HSD17B10LMNAALOX15TSHRSMN1; SMN2 | |
| SCHEMBL26835550 | 0.73 | L3MBTL1 (0.59) | HSD17B10LMNAALOX15TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | HSD17B10 3013/4885LMNA 4118/4885ALOX15 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.